Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Cost of Revenue: 2009-2025

Historic Cost of Revenue for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to $71.0 million.

  • Myriad Genetics' Cost of Revenue rose 1.57% to $71.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $284.1 million, marking a year-over-year decrease of 13.04%. This contributed to the annual value of $284.1 million for FY2024, which is 1.76% down from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Cost of Revenue is $71.0 million, which was down 1.25% from $71.9 million recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Cost of Revenue peaked at $118.7 million during Q4 2022, and registered a low of $44.1 million during Q1 2021.
  • In the last 3 years, Myriad Genetics' Cost of Revenue had a median value of $69.9 million in 2024 and averaged $71.4 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first slumped by 44.55% in 2021, then spiked by 159.17% in 2022.
  • Quarterly analysis of 5 years shows Myriad Genetics' Cost of Revenue stood at $45.8 million in 2021, then spiked by 159.17% to $118.7 million in 2022, then declined by 3.45% to $114.6 million in 2023, then plummeted by 37.17% to $72.0 million in 2024, then rose by 1.57% to $71.0 million in 2025.
  • Its last three reported values are $71.0 million in Q3 2025, $71.9 million for Q2 2025, and $69.2 million during Q1 2025.